Aptevo

$31.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.99 (-3.05%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Aptevo and other stocks, options, and ETFs commission-free!

About APVO

Aptevo Therapeutics Inc. Common Stock, also called Aptevo, is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA. The listed name for APVO is Aptevo Therapeutics Inc. Common Stock.

CEO

Marvin L. White

Employees

Headquarters

Seattle, Washington

Founded

2016

Market Cap

144.68M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

74.98K

High Today

$33.09

Low Today

$31.04

Open Price

$32.51

Volume

94.08K

52 Week High

$60.00

52 Week Low

$2.94

Collections

APVO News

MarketWatchJan 16

Aptevo Therapeutics Inc. Stock Quote (U.S.: Nasdaq)

Aptevo Therapeutics Inc. Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of nove

APVO Earnings

-$2.41

-$1.61

-$0.80

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 25, After Hours